BioCentury
ARTICLE | Company News

Molecular Partners, Allergan deal

September 7, 2015 7:00 AM UTC

Molecular Partners will receive $35 million in accelerated milestone payments from Allergan Inc., now Allergan plc (NYSE:AGN, Dublin, Ireland), in connection with two ophthalmic deals. The companies partnered in May 2011 to develop and commercialize abicipar pegol ( MP0112) and in August 2012 to develop and commercialize MP0260 and to design and develop designed ankyrin repeat proteins (DARPins) against undisclosed targets. ...